FDA,pembrolizumab,Oncology,Immunotherapy,FDAApproval,HNSCC,CancerResearch

Mashup Score: 0

FDA Approves Pembrolizumab for Adults with Resectable Locally Advanced Head, Neck Squamous Cell Carcinoma - 11 day(s) ago

The FDA announced on June 12 that it has approved pembrolizumab for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1.

Source: www.consultant360.com

Categories: General Medicine News

Tweet Tweets with this article
- Consultant360
  
  🚨 On June 12, 2025, the #FDA approved #pembrolizumab for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) expressing PD-L1. 📄 Full story: https://t.co/DCl7Od9CUJ #Oncology #Immunotherapy #FDAApproval #HNSCC #CancerResearch https://t.co/WSgX8kIlv5